Dapagliflozin Improves Kidney Function in the Adenine-Induced Mouse Model of Chronic Kidney Disease
Background & aim: Translational models are essential to identify improved treatment options for chronic kidney disease (CKD) patients. However, most preclinical CKD models do not demonstrate reduced glomerular filtration rate (GFR) or improvement by standard of care (SoC). The aim…
Differential therapeutic profile of efruxifermin in the CDAA-HFD and GAN DIO-MASH mouse models
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunctionassociated steatohepatitis (MASH). Efruxifermin (EFX) is a long acting FGF21 analogue currently in phase 3…
Semaglutide improves metabolic and histological outcomes and reverses clinically relevant biomarker alterations in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
Background & aim: The long-acting glucagon-like peptide-1 (GLP1) receptor agonist semaglutide was recently approved as the first GLP-1–based therapy for people with MASH and moderate-to-severe fibrosis. Clinical studies have demonstrated that semaglutide not only improves liver histology but also reverses…
Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model
Background & aim: Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as promising therapeutic candidates for metabolic dysfunction-associated steatohepatitis (MASH). Importantly, semaglutide was recently approved as the first GLP-1-based treatment for people with MASH with moderate-to-severe fibrosis. Translational models that recapitulate…
Survodutide, a novel dual GLP-1 receptor/glucagon receptor agonist, improves kidney health in a mouse model of advanced diabetic kidney disease
Background & aim: Glucagon influences kidney function through both direct intrarenal glucagon receptor (GCGR) signaling and indirect humoral pathways. Increasing evidence suggests that renal GCGR activity is impaired in chronic kidney disease (CKD). Survodutide is a novel, long-acting dual GCGR/GLP-1…
Superior Efficacy and Clinical Translatability of CagriSema Compared to Cagrilintide and Semaglutide in the DIO rats
Background & aim: Long-acting amylin analogues offer mechanistic complementarity to incretin-based therapies for obesity. Accordingly, CagriSema, a fixed-dose combination of the amylin analogue Cagrilintide and the GLP-1 analogue Semaglutide, has demonstrated superior weight loss compared with either agent alone in recent clinical trials…
Automated AI-assisted preantral ovarian follicle staging in a mouse model of chemotherapy- induced primary ovarian insufficiency
Background & aim: Classification and counting of ovarian follicles is a key endpoint in preclinical models of reproductive disorders. Traditionally, this relies on manual histopathological scoring subjecting to inter- and intra-observer variability, thus affecting reproducibility. This study aimed to validate GHOST (Gubra…
Differential Therapeutic Profile of Efruxifermin in the GAN DIO-MASH and CDAA-HFD Mouse Models of MASH
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX) is a long-acting FGF21 analogue currently inphase 3 clinical development for pre-cirrhotic…
Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development
Background: Injectable peptide-based glucagon-like peptide-1 receptor (GLP1R) agonists (GLP1RAs) are effective treatments for obesity and diabetes but are limited by patient compliance and scalability challenges. In contrast, non-peptide small-molecule GLP1RAs offer the advantage of oral delivery but are relatively inactive…